In this post-hoc analysis of the Phase 3 ION trials evaluating HCV therapy with ledipasvir/sofosbuvir ± ribavirin, current opioid substitution therapy and ongoing drug use during therapy did not impact treatment completion, adherence, sustained virologic response, and safety.
INTRODUCTION
Hepatitis C virus (HCV) infection disproportionally affects people who inject drugs (PWID) [1] . The burden of HCV-related liver disease is increasing among PWID, particularly among older individuals who have been infected for many years [1] . For recent initiates into drug injecting, the risk of acquiring HCV is high and HCV transmission continues among PWID in many settings [2] [3] [4] . Therefore, effective HCV treatment for PWID is necessary to prevent the development and progression of liver disease and stop onward transmission [5, 6] .
Strategies enhancing HCV testing, linkage to care and treatment are needed.
People with a history of injecting drug use include former injectors who have ceased injecting and "recent PWID" (definitions for "recent" vary from one month to 12 months) [7] . People with a history of injecting drug use may also be receiving opioid substitution therapy (OST, methadone or buprenorphine) for management of opioid dependence, some of whom may also have recently injected drugs.
Interferon-based therapy is safe and effective among those with a history of injecting drug use, people receiving OST and those with recent drug use prior to or during therapy, with A c c e p t e d M a n u s c r i p t 4 responses similar to that observed in large clinical trials [8] [9] [10] . However, data are lacking on HCV treatment outcomes with interferon-free direct-acting antiviral agents (DAAs) among PWID receiving OST or people with illicit drug use during HCV therapy.
Many payers in the United States have implemented restrictions excluding those who have recently used illicit drugs, injecting drugs, or are receiving OST from interferon-free HCV therapies (irrespective of disease stage) [11] . An argument used for restricting access has been the lack of data on treatment outcomes with interferon-free HCV therapies in these populations. However, this is not consistent with international guidelines from the American Association for the Study of Liver Disease (AASLD)/Infectious Diseases Society of America (IDSA), the European Study for the Association of the Liver (EASL), the International Network for Hepatitis in Substance Users (INHSU), and the World Health Organization (WHO), all of whom recommend interferon-free HCV treatment for PWID [5, [12] [13] [14] [15] and suggest PWID should be prioritized given the potential to reduce transmission [6] .
Interferon-free DAA HCV therapy for recent PWID is also cost-effective, given the prevention benefits [16] .
The Phase 3 ION trials evaluated the efficacy and safety of ledipasvir/sofosbuvir ± ribavirin in patients with chronic genotype 1 HCV infection [17] [18] [19] . People receiving stable OST were eligible for inclusion, but people with clinically relevant illicit drug use within 12 months of screening were excluded from study participation (confirmed by urine drug test). However, illicit drug use in the period following treatment initiation did not lead to subsequent discontinuation from these trials. Although these clinical trial populations are highly selected, included people on stable OST, excluded people with recent drug use, and may not be 
METHODS

Study Participants and Design
Study Endpoints
In this analysis, the endpoints included treatment completion, adherence (≥80% of doses), 
RESULTS
Participant Characteristics
Of the 1952 patients enrolled and treated in the ION trials (ION-1, n=865; ION-2, n=440;
ION-3, n=647), 70 (4%) were receiving OST at enrolment. The clinical characteristics of the study participants are shown in Table 1 . Among people receiving OST, 69% (n=48) of participants received ledipasvir/sofosbuvir, 31% (n=22) received ledipasvir/sofosbuvir + ribavirin, 90% (n=63) had no cirrhosis, and 89% (n=62) were treatment-naïve. Among those not receiving OST, 55% (n=1032) of participants received ledipasvir/sofosbuvir, 45% A c c e p t e d M a n u s c r i p t 8 (n=850) received ledipasvir/sofosbuvir + ribavirin, 88% (n=1660) had no cirrhosis, and 77%
(n=1450) were treatment-naïve.
Among the 865 patients treated with ledipasvir/sofosbuvir ± ribavirin in the ION-1 study, 853
patients had a Week 8 or Week 12 serum sample available for retrospective testing of drugs (Table 2) . Overall, 15% (126/853) tested postitive for cannibinoids alone and 8% (70/853) tested positive for any drug use not explained by prescribed medications (± cannabinoids).
Among those testing positive for any drug use not explained by prescribed medications (± cannabinoids), this included non-prescribed benzodiazepines (n=19, 27%),
opiates/oxycodone/methadone (n=11, 16%), cocaine (n=9, 13%), methamphetamine/amphetamine (n=7, 10%), and barbiturates (n=7, 10%). The baseline characteristics stratified by drug use during therapy were similar in the three groups (Table   3) .
HCV Treatment Completion
The proportion of participants completing HCV therapy was 97% (68/70; 95% CI: 90% to >99%) among participants receiving OST, compared to 98% (1846/1882; 95% CI: 97% to 99%) among those not receiving OST (P = 0.40, Table 4 ). The reasons for treatment discontinuation among people receiving OST (n = 2) included one participant who withdrew consent and one participant with lack of efficacy. The reasons for treatment discontinuation among people not receiving OST (n = 36) included AEs (n = 13), consent withdrawal (n = 6);
protocol violation (n = 6); lack of efficacy (n = 1); non-compliance (n = 1); pregnancy (n = A c c e p t e d M a n u s c r i p t 9   Table 4 ) compared with those with cannabinoid use only (98%, 95% CI: 94% to >99%; P = 1.00) or those with any illicit drugs ± cannabinoids (97%, 95% CI: 90% to >99%; P = 0.66).
HCV Treatment Adherence
The proportion of participants with ≥80% adherence to therapy was 93% (65/70; 95% CI:
84% to 98%) among participants receiving OST, compared to 92% (1737/1882; 95% CI:
91% to 93%) among those not receiving OST (P = 1.00, Table 3 ). The proportion of participants with ≥80% adherence to therapy was similar among those with no illicit drug use during therapy (91%, 95% CI: 89% to 93%; Table 4 ) compared to those with cannabinoid use only (92%, 95% CI: 86% to 96%; P = 0.86) or those with any illicit drugs ± cannabinoids (91%, 95% CI: 82% to 97%; P = 1.00).
HCV Treatment Outcomes
Among all participants receiving ledipasvir/sofosbuvir (± ribavirin), the proportion with SVR12 among those receiving OST (94%, 95% CI: 86% to 98%) was similar to those not receiving OST (97%, 95% CI: 96% to 98%; P = 0.28, Table 3 ). SVR12 stratified by treatment duration for participants receiving and not receiving OST is shown in Figure 1 .
There was no difference in SVR12 in those receiving methadone and buprenorphine, respectively [95% (95% CI: 83% to 99%) vs. 93% (95% CI: 77% to 99%), P = 1.00]. The proportion of participants with SVR12 was similar among those no illicit drug use during therapy (99%, 95% CI: 98% to >99%; Table 4 ) compared to those with cannabinoid use only (98%, 95% CI: 93% to >99%; P = 0.12) or those with any illicit drugs ± cannabinoids (97%, 95% CI: 90% to >99%; P = 0.14). Among those with any illicit drugs ± cannabinoids (n=70), there was no difference in SVR12 among those receiving and not receiving OST [100% (95% CI: 74% to 100%) vs. 97% (95% CI: 88% to >99%), P = 1.00). A c c e p t e d M a n u s c r i p t
Safety
The proportion with AEs [89% (95% CI: 79% to 95%) vs 80% (95% CI: 78% to 81%), P = 0.07; Tables 4 and 5 ] and serious AEs [4% (95% CI: 1% to 12%) vs 3% (95% CI: 2% to 3%), P = 0.43, Tables 4 and 5) were similar among participants receiving and not receiving OST.
AEs were mostly mild or moderate in severity. Hemoglobin levels <10 g/dL were mainly limited to those who received ledipasvir/sofosbuvir + ribavirin, in those receiving and not receiving OST (5% vs 7%, P = 1.00). The proportion of participants with AEs was similar among those with no illicit drug use during therapy (86%, 95% CI: 83% to 88%; Table 4) compared to those with cannabinoid use only (83%, 95% CI: 75% to 89%; P = 0.34) or those with any illicit drugs and cannabinoids (90%, P = 0.46). The proportion of participants with serious AEs was similar among those with no illicit drug use during therapy (4%, 95% CI: 3% to 6%; Table 4 ) compared to those with cannabinoid use only (2%, 95% CI: <1% to 6%; P = 0.21) or those with any illicit drugs ± cannabinoids (4%, 95% CI: 1% to 12%; P = 1.00).
HCV Reinfection
There were no cases of documented reinfection or relapse between post-treatment week 12
and post-treatment week 24. There were no cases of HCV reinfection observed in this study through 24 weeks after treatment completion. This is consistent with low HCV reinfection rates of 1-4% per 100
DISCUSSION
person-years following successful interferon-based therapy among PWID that have previously been reported [9, 24, 25] . However, the sample size and duration of follow-up in this study are limited and further long-term studies of HCV reinfection among PWID are required to more fully characterize the risk of HCV reinfection and associated risk factors.
This study has several other limitations. People with active drug use at baseline were excluded from participating in the ION trials, and as such, enrolled participants represented a selected population likely to be engaged in care. Therefore, these findings may not be generalizable to other PWID populations (particularly those not receiving stable OST or recent PWID). Additionally, the sample size of participants receiving OST with ongoing drug use excluding cannabinoids was small. Further, this was a post-hoc analysis of the Phase 3 ION studies and this analysis was not specified a priori. Given the paucity of data on interferon-free treatment outcomes among people receiving OST and people with illicit drug use, these data still provide important guidance for HCV management in these populations.
There remains a reluctance to treat HCV infection among PWID (including those receiving OST A c c e p t e d M a n u s c r i p t 13 [11] . Justifications for these restrictions towards PWID are typically described as lack of adherence to the treatment regimen, worse outcomes than non-PWID at comparable disease stages, likelihood of HCV reinfection, and lack of data on treatment outcomes with interferon-free DAA HCV therapies [11, 26] . Decisions to provide DAA HCV treatments to people with drug and alcohol use, including PWID, must be undertaken on the basis of clinical and public health requirements rather than a common co-existing disorder, such as addiction [26] . These data argue against restrictions for DAA therapy that are being imposed on PWID in some countries and provide important data to inform international recommendations for the management of HCV among PWID [12] [13] [14] [15] .
In conclusion, these data demonstrate that ledipasvir/sofosbuvir HCV therapy is well A c c e p t e d M a n u s c r i p t 24 
